Legacy not for routinely commissioned policies for drugs now in tariff effective April 2026
- Everolimus for prevention of organ rejection following heart transplantation
- Infliximab (remicade) as anti-TNF alpha treatment option for paediatric patients with severe refractory uveitis
- Infliximab for progressive pulmonary sarcoidosis in adults
- Infliximab for the treatment of hidradenitis suppurativa
- Rituximab for chronic inflammatory demyelinating polyradiculoneuropathy (CIDP), multifocal motor neuropathy (MMN) and vasculitis of the peripheral nervous system (adults)
- Rituximab for connective tissue disease associated with interstitial lung disease
- Rituximab for the treatment of primary Sjogren’s syndrome (PSS) in adults
- Rituximab for the treatment of refractory focal segmental glomerulosclerosis in the native kidney in adults
- Ustekinumab for refractory Crohn’s disease in pre-pubescent children
- Use of Adalimumab for refractory chronic non-bacterial osteomyelitis/osteitis (CNO) (all ages)